EDIT
NASDAQ · Biotechnology
Editas Medicine Inc
$2.75
+0.18 (+7.00%)
Financial Highlights (FY 2026)
Revenue
68.37M
Net Income
-270,072,021
Gross Margin
—
Profit Margin
-395.0%
Rev Growth
+27.2%
D/E Ratio
2.15
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 64.4% | 64.4% |
| Operating Margin | -394.9% | -355.4% | 24.8% | 21.2% |
| Profit Margin | -395.0% | -375.3% | 14.4% | 17.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 68.37M | 53.77M | 30.54M | 27.97M |
| Gross Profit | — | — | 19.66M | 18.00M |
| Operating Income | -269,992,319 | -191,107,422 | 7.57M | 5.94M |
| Net Income | -270,072,021 | -191,163,837 | 4.38M | 4.75M |
| Gross Margin | — | — | 64.4% | 64.4% |
| Operating Margin | -394.9% | -355.4% | 24.8% | 21.2% |
| Profit Margin | -395.0% | -375.3% | 14.4% | 17.0% |
| Rev Growth | +27.2% | +27.2% | +16.6% | +5.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 132.82M | 132.82M | 59.55M | 55.44M |
| Total Equity | 61.84M | 61.84M | 93.22M | 102.72M |
| D/E Ratio | 2.15 | 2.15 | 0.64 | 0.54 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -261,087,589 | -195,071,340 | 9.59M | 9.00M |
| Free Cash Flow | — | — | 5.15M | 6.45M |